Literature DB >> 11005674

Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells.

M Styblo1, L M Del Razo, L Vega, D R Germolec, E L LeCluyse, G A Hamilton, W Reed, C Wang, W R Cullen, D J Thomas.   

Abstract

Biomethylation is considered a major detoxification pathway for inorganic arsenicals (iAs). According to the postulated metabolic scheme, the methylation of iAs yields methylated metabolites in which arsenic is present in both pentavalent and trivalent forms. Pentavalent mono- and dimethylated arsenicals are less acutely toxic than iAs. However, little is known about the toxicity of trivalent methylated species. In the work reported here the toxicities of iAs and trivalent and pentavalent methylated arsenicals were examined in cultured human cells derived from tissues that are considered a major site for iAs methylation (liver) or targets for carcinogenic effects associated with exposure to iAs (skin, urinary bladder, and lung). To characterize the role of methylation in the protection against toxicity of arsenicals, the capacities of cells to produce methylated metabolites were also examined. In addition to human cells, primary rat hepatocytes were used as methylating controls. Among the arsenicals examined, trivalent monomethylated species were the most cytotoxic in all cell types. Trivalent dimethylated arsenicals were at least as cytotoxic as trivalent iAs (arsenite) for most cell types. Pentavalent arsenicals were significantly less cytotoxic than their trivalent analogs. Among the cell types examined, primary rat hepatocytes exhibited the greatest methylation capacity for iAs followed by primary human hepatocytes, epidermal keratinocytes, and bronchial epithelial cells. Cells derived from human bladder did not methylate iAs. There was no apparent correlation between susceptibility of cells to arsenic toxicity and their capacity to methylate iAs. These results suggest that (1) trivalent methylated arsenicals, intermediary products of arsenic methylation, may significantly contribute to the adverse effects associated with exposure to iAs, and (2) high methylation capacity does not protect cells from the acute toxicity of trivalent arsenicals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005674     DOI: 10.1007/s002040000134

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  205 in total

Review 1.  Microbial methylation of metalloids: arsenic, antimony, and bismuth.

Authors:  Ronald Bentley; Thomas G Chasteen
Journal:  Microbiol Mol Biol Rev       Date:  2002-06       Impact factor: 11.056

2.  Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1.

Authors:  Helen Denton; Joanne C McGregor; Graham H Coombs
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

3.  Indigenous American ancestry is associated with arsenic methylation efficiency in an admixed population of northwest Mexico.

Authors:  Paulina Gomez-Rubio; Yann C Klimentidis; Ernesto Cantu-Soto; Maria M Meza-Montenegro; Dean Billheimer; Zhenqiang Lu; Zhao Chen; Walter T Klimecki
Journal:  J Toxicol Environ Health A       Date:  2012

Review 4.  Influence of arsenate and arsenite on signal transduction pathways: an update.

Authors:  Ingrid L Druwe; Richard R Vaillancourt
Journal:  Arch Toxicol       Date:  2010-05-26       Impact factor: 5.153

5.  Associations between the polymorphisms of GSTT1, GSTM1 and methylation of arsenic in the residents exposed to low-level arsenic in drinking water in China.

Authors:  Jinyou Yang; Li Yan; Min Zhang; Yijun Wang; Chun Wang; Quanyong Xiang
Journal:  J Hum Genet       Date:  2015-04-16       Impact factor: 3.172

6.  Using mathematical modeling to infer the valence state of arsenicals in tissues: A PBPK model for dimethylarsinic acid (DMAV) and dimethylarsinous acid (DMAIII) in mice.

Authors:  Lydia M Bilinsky; David J Thomas; Jeffrey W Fisher
Journal:  J Theor Biol       Date:  2018-10-26       Impact factor: 2.691

7.  Arsenic Exposure in Relation to Ischemic Stroke: The Reasons for Geographic and Racial Differences in Stroke Study.

Authors:  Cari L Tsinovoi; Pengcheng Xun; Leslie A McClure; Vivian M O Carioni; John D Brockman; Jianwen Cai; Eliseo Guallar; Mary Cushman; Frederick W Unverzagt; Virginia J Howard; Ka He
Journal:  Stroke       Date:  2017-12-06       Impact factor: 7.914

8.  Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase.

Authors:  Zuzana Drobná; Stephen B Waters; Vicenta Devesa; Anne W Harmon; David J Thomas; Miroslav Stýblo
Journal:  Toxicol Appl Pharmacol       Date:  2005-09-01       Impact factor: 4.219

9.  Methylarsonous acid causes oxidative DNA damage in cells independent of the ability to biomethylate inorganic arsenic.

Authors:  Erik J Tokar; Chikara Kojima; Michael P Waalkes
Journal:  Arch Toxicol       Date:  2013-10-05       Impact factor: 5.153

10.  Genetic association between intronic variants in AS3MT and arsenic methylation efficiency is focused on a large linkage disequilibrium cluster in chromosome 10.

Authors:  Paulina Gomez-Rubio; Maria M Meza-Montenegro; Ernesto Cantu-Soto; Walter T Klimecki
Journal:  J Appl Toxicol       Date:  2010-04       Impact factor: 3.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.